Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
Status:
Withdrawn
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Secondary hyperaldosteronism and the non-osmotic release of arginine vasopressin (AVP) are
the major factors in sodium and water retention in pulmonary arterial hypertension with right
ventricular failure. Natriuretic doses of mineralocorticoid antagonist and aquaretic doses of
V2 receptor antagonist will attenuate the sodium and water retention respectively, and be
associated with clinical improvement.